Routine compliance filing for share demat details for Sep 2026 quarter

Compliance View source PDF Explain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.9%Reaction day

₹1101.40

prior close

₹1100.60

announcement price

After-mkt

timing

Nifty Microcap 250market-2.8%+0.8% vs market

Pharmaceuticals peers, median of 172sector-2.5%+0.5% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.5

15m

-0.9

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.9-2.8+0.8-2.5+0.5

Next day

-0.1-2.5+2.4-2.6+2.5

-1.0-1.7+0.6-2.5+1.5

-1.4-1.5+0.1-2.6+1.2

-1.8-0.8-1.0-2.5+0.8

-3.6-2.4-1.1-3.2-0.4

-7.4-3.4-4.0-4.3-3.1

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Strides Pharma Science submitted quarterly certificates from its registrar KFin Technologies to NSDL and CDSL, confirming that share dematerialisation and rematerialisation details for the quarter ended September 30, 2026 have been shared with the stock exchanges. This is a standard filing required under SEBI regulation 74(5) of the Depositories and Participants Regulations 2018.

Likely market impact

Routine regulatory compliance; no impact on business, financials, or shareholders.